The development of immune checkpoint inhibitors (ICIs) has significantly advanced cancer treatment. However, their efficacy is not consistent across all patients, underscoring the need for personalized approaches. In this study, we examined the relationship between activated CD4^(+) memory T cell expression and ICI responsiveness. A notable correlation was observed between increased activated CD4^(+) memory T cell expression and better patient survival in various cohorts. Additionally, …